Screener
Veradermics MANE Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Veradermics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Veradermics’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 5:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001827635-26-000019
| (in thousands) | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Purchase of property, plant and equipment | — | (19) |
| Purchases of marketable securities | (122,988) | (15,731) |
| Maturities of marketable securities | 21,689 | — |
| Net cash used in investing activities | (101,299) | (15,750) |
| Cash flows from financing activities: | ||
| Issuance of Series B preferred stock, net of issuance costs paid | — | 8,423 |
| Initial public offering, net of issuance costs paid | 269,102 | — |
| Exercise of stock options | 11 | — |
Item 1. Condensed Consolidated Financial Statements (
FAQ
- What is Veradermics's investing cash flow?
- Veradermics (MANE) reported investing cash flow of -$101.3M in Q1 2026.
- How has Veradermics's investing cash flow changed year-over-year?
- Veradermics's investing cash flow decreased by 543.2% year-over-year, from -$15.75M to -$101.3M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Veradermics's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude